Testing New Drugs for SSc: A Single Group, Open Label, Pilot Clinical Trial of Nilotinib (Tasignaâ„˘) Second generation tyrosine kinase inhibitor (TKI) drugs aim to be more efficacious with less side effects. A recent pilot study of one such TKI called nilotinib (Tasignaâ„˘) was completed by 7 patients with diffuse cutaneous (dc) systemic sclerosis (SSc) for less than 3 years. The twice daily 400 mg oral dose of nilotinib was tolerated by the majority of patients in the study. Tolerability was limited primarily by mildly prolonged QTc, which is a known side effect of nilotinib and an exclusion criterion for continuation in this study. Modified Rodnan Skin Score (MRSS) improved significantly with 6 months of treatment in this very early and active group of patients. Further testing in randomized placebo controlled trials will ultimately be necessary to determine whether the benefits seen were truly related to the medication tested. Full Details on HSS.edu
Authors HSS: Jessica K. Gordon, MD Morgana L. Davids Kamini Doobay Stephen L. Lyman, PhD Mary K. Crow, MD Robert F. Spiera, MD Weill-Cornell Medical Center: Cynthia Magro, MD Horatio F. Wildman, MD Presented by Dr. Gordon (pictured) at the 2012 ACR Annual Meeting
Learn more about the HSS Rheumatology Research Studies presented at the 2012 ACR Meeting.